Related Experiment Video
Updated: Apr 29, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
20.2K
Pharmacogenetic biomarkers for predicting drug response
Paul Christiaan Bank1, Joachim Jesse Swen, Henk-Jan Guchelaar
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Expert Review of Molecular Diagnostics
|May 27, 2014
Summary
Genetics significantly impacts drug response, but clinical application of pharmacogenetics (PGx) is slow. This review outlines key considerations for integrating PGx into routine patient care.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Genetics
Background:
- Interpatient variability in drug response is well-documented.
- The influence of genetics on drug therapy outcomes has been known for over 50 years.
- Translating genetic knowledge into routine clinical practice remains a challenge.
Purpose of the Study:
- To discuss critical considerations for implementing pharmacogenetics (PGx) into routine clinical care.
- To highlight factors influencing the slow adoption of PGx in practice.
- To provide a framework for understanding PGx integration challenges.
Main Methods:
- Review of existing literature and clinical practice examples.
- Discussion of six key implementation considerations for PGx.
- Analysis of factors affecting PGx translation to clinical settings.
Main Results:
- Identified six essential considerations for PGx implementation: biomarker necessity, sources of genetic variability, explained variability by PGx, actionability of PGx results, evidence requirements, and data interpretation resources.
- Highlighted the gap between genetic knowledge and its clinical application.
- Emphasized the need for clear guidelines and evidence for PGx adoption.
Conclusions:
- Successful implementation of pharmacogenetics requires addressing specific challenges.
- Actionable PGx data and robust evidence are crucial for clinical integration.
- Further efforts are needed to bridge the gap between pharmacogenetic research and patient care.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:29Pharmacogenetics and Pharmacogenomics: Overview
248
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
248
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:27Principles of Pharmacogenetics: Types of Genetic Variants
137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81